



Apersy

Value | Commercial | Access

February 2023 Market
Access news recap

READING LIST edition*

Evidence & Access



[French HAS considerations and consultation of speeding up market access while ensuring appropriate HTA standards and evidence standards for Health tech](#)

Digital & AI



[Did you know? -The famous German DiGA process does not include prevention apps in its assessment remit! But the statutory health insurance covers prevention courses that have been certified by the *Zentrale Prüfstelle Prävention*. There are already many certified online courses, now the first apps are being included into reimbursement coverage \[GERMAN\]](#)

Value & Reimbursement



[Highly personalised, never-seen-before treatments and the growing complex care environments need a rethinking of reimbursing health products, care and outcomes](#)

[Resonating with Apersy's take on the evolving value definition\(s\) in healthcare, a closer look at how patients perceive value, how value definition and creation is and must change for all stakeholders](#)

Microbiome & innovative Biotech



[Hemgenix - the first gene therapy for haemophilia B - is ready for European launch with conditional marketing authorization \(CMA\)](#)

[After its November approval, Rebyota - the first and only FDA-approved Microbiome-Based Treatment for the prevention of recurrence of C. diff infection - is now available in the US](#)

For more updates on how payers think about value and evaluate health tech products, connect or get in touch



contact@apersy.com



www.apersy.com



www.linkedin.com/company/apersy/